Wells Fargo Maintains Underweight on Clorox, Lowers Price Target to $120
Wells Fargo analyst Chris Carey maintains Clorox (NYSE:CLX) with a Underweight and lowers the price target from $130 to $120.
3 Stocks To Turn Dividend Payments Into Passive Monthly Income
A dividend is a distribution, to eligible shareholders, from corporate profits. The payments, the amount of the payments, the payment schedule, etc. vary from company to company and is determined by the board of directors.
Barclays Maintains Underweight on Clorox, Lowers Price Target to $115
Barclays analyst Lauren Lieberman maintains Clorox (NYSE:CLX) with a Underweight and lowers the price target from $126 to $115.
DA Davidson Maintains Neutral on Clorox, Lowers Price Target to $123
DA Davidson analyst Linda Bolton Weiser maintains Clorox (NYSE:CLX) with a Neutral and lowers the price target from $127 to $123.
Recap: Clorox Q3 Earnings
Clorox (NYSE:CLX) reported its Q3 earnings results on Monday, May 2, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
Clorox beat estimated earnings by 35.05%, reporting an EPS of $1.31 versus an estimate of $0.97.
Why Clorox Shares Are Sliding After Hours
Clorox Co (NYSE: CLX) shares are trading lower in Monday's after-hours session after the company reported financial results and cut its full-year earnings forecast.
Clorox Q3 EPS $1.31 Beats $0.97 Estimate, Sales $1.80B Inline
Clorox (NYSE:CLX) reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $0.97 by 35.05 percent. This is a 19.14 percent decrease over earnings of $1.62 per share from the same period
Earnings Preview For Clorox
Clorox (NYSE:CLX) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement.
Analysts estimate that Clorox will report an earnings per share (EPS) of $0.97.
Barclays Maintains Underweight on Clorox, Lowers Price Target to $117
Barclays analyst Lauren Lieberman maintains Clorox (NYSE:CLX) with a Underweight and lowers the price target from $132 to $117.
